RxDoctor Payments Data

George Kannarkat, MD

Internal Medicine · Newport News, VANPI 1992856579

Payments from drug & device makers

$1,276in general payments, 2019–2025

Across 32 payments — averaging $39.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$525
  • Comsort, Inc$100
  • Array Biopharma Inc$75
  • Pfizer$67
  • Daiichi Sankyo Inc.$62
  • Medtronic$56
  • plus $390 from 12 others

What the payments were for

  • Consulting fees$62549%
  • Travel & lodging$564%
  • Food & beverage$53342%
  • Education$625%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,276 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$149,726
Medicare patients
445
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide64$1,059,331
XtandiEnzalutamide41$574,750
BrukinsaZanubrutinib45$555,831
CalquenceAcalabrutinib Maleate22$333,300
VonjoPacritinib Citrate11$282,396
FruzaqlaFruquintinib13$263,053
TagrissoOsimertinib Mesylate15$242,468
VenclextaVenetoclax20$235,379
ImbruvicaIbrutinib24$230,776
MekinistTrametinib Dimethyl Sulfoxide12$186,635
TafinlarDabrafenib Mesylate11$150,412
Abiraterone Acetate44$146,511
TabrectaCapmatinib Hydrochloride11$136,082
PomalystPomalidomide17$130,670
Lenalidomide25$122,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$27$1,059,33164 claims
AstraZenecaCalquence, Tagrisso$525$575,76837 claims
NovartisMekinist, Tafinlar, Tabrecta$30$473,12934 claims
AbbVieVenclexta$54$235,37920 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$37$130,67017 claims
PfizerEliquis$67$117,125146 claims
Johnson & JohnsonXarelto$53$35,55533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →